| Keywords: |
cancer chemotherapy; treatment outcome; medical oncologist; fluorouracil; liver cell carcinoma; patient selection; liver neoplasms; outcome assessment; antineoplastic agent; quality control; antineoplastic combined chemotherapy protocols; morbidity; editorial; practice guideline; vascularization; data base; information processing; risk factor; patient care; liver metastasis; total quality management; liver tumor; patient safety; surgical infection; intraarterial drug administration; infusions, intra-arterial; liver disease; accreditation; clinical decision making; therapy effect; feedback system; disease management; liver abscess; conceptual framework; hepatic artery; venous thromboembolism; infusion pumps, implantable; biliary tract disease; clinical outcome; surgical oncology; biliary sclerosis; cholangitis; gastroduodenal artery; colorectal liver metastasis; humans; human; surgical oncologist; hepatic artery infusion chemotherapy; multidisciplinary team; safety procedure; program feasibility; coronavirus disease 2019; program sustainability
|
